HB Wealth Management LLC decreased its stake in shares of HCA Healthcare, Inc. (NYSE:HCA – Free Report) by 16.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,446 shares of the company’s stock after selling 1,282 shares during the period. HB Wealth Management LLC’s holdings in HCA Healthcare were worth $2,513,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the stock. Saudi Central Bank raised its holdings in HCA Healthcare by 85.8% during the second quarter. Saudi Central Bank now owns 10,955 shares of the company’s stock worth $4,271,000 after purchasing an additional 5,059 shares in the last quarter. AlphaGrep UK Ltd acquired a new position in shares of HCA Healthcare during the 2nd quarter valued at $1,079,000. Premier Path Wealth Partners LLC lifted its holdings in shares of HCA Healthcare by 6.4% in the second quarter. Premier Path Wealth Partners LLC now owns 2,450 shares of the company’s stock valued at $955,000 after buying an additional 148 shares during the period. Concurrent Investment Advisors LLC grew its holdings in HCA Healthcare by 14.5% during the second quarter. Concurrent Investment Advisors LLC now owns 3,197 shares of the company’s stock worth $1,246,000 after acquiring an additional 404 shares during the period. Finally, NEOS Investment Management LLC lifted its holdings in HCA Healthcare by 12.0% in the 2nd quarter. NEOS Investment Management LLC now owns 25,349 shares of the company’s stock valued at $9,883,000 after acquiring an additional 2,724 shares during the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.
HCA Healthcare Stock Down 0.8% Shares of NYSE:HCA opened at $401.80 on Wednesday. The company has a market cap of $86.99 billion, a P/E ratio of 13.45, a price-to-earnings-growth ratio of 1.33 and a beta of 1.10. The company’s fifty day moving average is $403.82 and its two-hundred day moving average is $434.97. HCA Healthcare, Inc. has a 12-month low of $353.99 and a 12-month high of $556.52.
HCA Healthcare (NYSE:HCA – Get Free Report) last issued its quarterly earnings results on Friday, July 24th. The company reported $7.59 earnings per share for the quarter, beating analysts’ consensus estimates of $7.56 by $0.03. HCA Healthcare had a negative return on equity of 244.79% and a net margin of 8.77%.The business had revenue of $20.23 billion for the quarter, compared to the consensus estimate of $19.76 billion. During the same quarter in the previous year, the company posted $6.84 earnings per share. HCA Healthcare’s revenue for the quarter was up 8.7% compared to the same quarter last year. Equities research analysts anticipate that HCA Healthcare, Inc. will post 29.42 earnings per share for the current year. HCA Healthcare Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 16th will be issued a dividend of $0.78 per share. This represents a $3.12 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Wednesday, September 16th. HCA Healthcare’s dividend payout ratio (DPR) is currently 10.45%.
Analysts Set New Price Targets A number of research firms recently commented on HCA. Deutsche Bank Aktiengesellschaft set a $476.00 target price on shares of HCA Healthcare in a report on Monday, July 27th. TD Cowen dropped their price target on HCA Healthcare from $500.00 to $431.00 and set a “buy” rating on the stock in a report on Monday, June 22nd. Oppenheimer reduced their price objective on HCA Healthcare from $520.00 to $485.00 and set an “outperform” rating for the company in a research note on Monday, July 27th. Jefferies Financial Group set a $450.00 target price on HCA Healthcare in a research report on Tuesday, July 14th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of HCA Healthcare in a research report on Friday. Fourteen research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $462.64.
Read Our Latest Analysis on HCA Healthcare
About HCA Healthcare (Free Report)
HCA Healthcare, Inc (NYSE:HCA) is a healthcare services company that operates hospitals and other healthcare facilities. Its network provides a broad range of medical services, including emergency care, inpatient and outpatient treatment, surgery, diagnostic services, and maternity care.
The company also operates ambulatory surgery centers, urgent care facilities, physician practices, and other outpatient locations. HCA Healthcare serves patients through facilities located across the United States, as well as through HCA Healthcare UK, its healthcare operations in the United Kingdom.
HCA Healthcare was founded in 1968 by Dr.
See Also Five stocks we like better than HCA Healthcare Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
HCA Healthcare (NYSE:HCA – Get Free Report) and OPKO Health (NASDAQ:OPK – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.
Valuation & Earnings This table compares HCA Healthcare and OPKO Health”s revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HCA Healthcare $75.60 billion 1.15 $6.78 billion $29.87 13.45 OPKO Health $606.90 million 1.96 -$225.68 million ($0.09) -17.67 HCA Healthcare has higher revenue and earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than HCA Healthcare, indicating that it is currently the more affordable of the two stocks. Profitability This table compares HCA Healthcare and OPKO Health’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets HCA Healthcare 8.77% -244.79% 11.10% OPKO Health -12.40% -5.88% -3.83% Analyst Recommendations This is a breakdown of recent ratings for HCA Healthcare and OPKO Health, as reported by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCA Healthcare 1 8 14 0 2.57 OPKO Health 1 3 1 0 2.00 HCA Healthcare currently has a consensus target price of $462.64, indicating a potential upside of 15.14%. OPKO Health has a consensus target price of $1.55, indicating a potential downside of 2.52%. Given HCA Healthcare’s stronger consensus rating and higher probable upside, analysts clearly believe HCA Healthcare is more favorable than OPKO Health.
Volatility & Risk HCA Healthcare has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.
Insider and Institutional Ownership 62.7% of HCA Healthcare shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 1.5% of HCA Healthcare shares are owned by company insiders. Comparatively, 44.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary HCA Healthcare beats OPKO Health on 9 of the 14 factors compared between the two stocks.
About HCA Healthcare (Get Free Report)
HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
About OPKO Health (Get Free Report)
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company's payer mix, which impacted revenue by approximately $400 million in the quarter.
On this news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
AlphaGrep UK Ltd acquired a new stake in shares of HCA Healthcare, Inc. (NYSE: HCA) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,767 shares of the company's stock, valued at approximately $1,079,000. A number of other hedge funds and other institutional
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company's payer mix, which impacted revenue by approximately $400 million in the quarter.
On this news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company's payer mix, which impacted revenue by approximately $400 million in the quarter.
On this news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
On August 25, 2026, we conducted a DCF analysis for HCA Healthcare Inc HCA, a company that has shown varied price performance recently. The stock has experienced a 6.0% increase over the past week and a 12.3% rise over the past month, although it is down 7.7% year-to-date. Over the past year, HCA has gained 6.7%.
DCF Earnings-based intrinsic value of $784.86 vs current price of $429.24 (margin of safety: 45.3%) DCF Free Cash Flow-based intrinsic value of $666.74 (second opinion) GF Score™ of 87/100 indicates a strong reliability of the DCF inputs What Is HCA Worth? DCF Earnings-Based Model In our DCF earnings-based model, we assume a two-stage growth approach. The first stage spans the next ten years, where we project an annual growth rate of 17.5% for earnings per share (EPS). The second stage accounts for a terminal growth rate of 4% for the subsequent ten years. The discount rate applied is 11%, which is derived from the sum of the risk-free rate and equity risk premium.
Parameter Value Current EPS (TTM, excl. non-recurring) $29.70 10-Year Growth Rate 17.5% 10-Year Treasury Rate 4.67% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% The calculation summary for the two stages is as follows:
Stage Description Value Growth Stage (Years 1-10) EPS growing at 17.5%, discounted at 11% $411.66 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $373.20 Intrinsic Value Growth + Terminal $784.86 With a current price of $429.24, HCA is significantly undervalued, presenting a margin of safety of 45.3%. It is important to note that GuruFocus utilizes EPS excluding non-recurring items, as research indicates a stronger correlation between stock prices and earnings than with free cash flow. For more details, you can visit the HCA DCF Calculator.
What Does the Free Cash Flow DCF Say? The Free Cash Flow (FCF)-based intrinsic value for HCA is calculated at $666.74. This figure aligns with the earnings-based valuation, further supporting the conclusion that HCA is significantly undervalued, with a margin of safety of 35.6%.
How Does GF Value™ Compare to the DCF Models? According to GuruFocus, the GF Value™ for HCA is $458.79, indicating that the stock is 6.4% undervalued. This proprietary measure is derived from historical trading multiples, past business growth, and future performance estimates. All three valuation models—DCF earnings, DCF FCF, and GF Value™—concur that HCA is undervalued, reinforcing the investment thesis. For further insights, check out the GF Value™.
What Does HCA's GF Score™ Tell Us? The GF Score™ evaluates a company's financial strength, profitability, growth potential, valuation, and momentum. HCA has a GF Score™ of 87/100, which suggests a strong overall performance. However, the predictability rank is 2 out of 5 stars, indicating that the DCF model may be less reliable for this stock due to its lower predictability. Below is a summary of HCA's GF Score™ metrics:
Metric Rating GF Score™ 87/100 Financial Strength 4/10 Profitability 10/10 Growth 10/10 Valuation 10/10 Momentum 2/10 For more details on HCA, visit the HCA stock page.
Key Assumptions and Limitations It is important to recognize that DCF models are highly sensitive to the assumptions made regarding growth and discount rates. Stocks with lower predictability ratings, like HCA, yield less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not fully capture future economic conditions.
What This Means for Investors In summary, all three valuation models—DCF earnings, DCF FCF, and GF Value™—indicate that HCA is significantly undervalued. The consensus among these models suggests a strong investment opportunity, although the lower predictability rank should be taken into account. Additionally, the guru ownership signal is noteworthy, with 13 gurus currently holding the stock, 9 of whom have increased their positions, while insiders have sold a total of $32.7 million over the past year. This mixed signal from insiders and gurus adds another layer of complexity to the investment decision. For further analysis, you can explore the HCA DCF Calculator.
Frequently Asked Questions What is HCA's intrinsic value based on DCF?
HCA's intrinsic value is $784.86 based on the earnings model and $666.74 based on the free cash flow model.
Is HCA overvalued or undervalued?
HCA is considered significantly undervalued based on both DCF models and the GF Value™.
How reliable is the DCF model for HCA?
The DCF model's reliability for HCA is limited, given its predictability rank of 2 out of 5 stars.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.
Key Takeaways HCA's cost-control progress is helping offset inflation and protect profitability amid earnings headwinds.HCA is using digital transformation and shared services to drive recurring productivity gains.HCA targets 4-6% long-term adjusted EBITDA growth as unit-cost control supports volume growth. HCA Healthcare, Inc. (HCA - Free Report) faces a significant earnings headwind from health insurance exchange disenrollment, with the company estimating a $1.0-$1.2 billion unfavorable impact in 2026. At the same time, professional fees and other operating costs remain elevated. Against this backdrop, its multi-year resiliency program is becoming an important tool for strengthening financial performance.
Same-facility cost per equivalent admission was essentially flat year over year in the second quarter and improved 1.4% sequentially. The combined cost of salaries and benefits, supplies, and other operating expenses per adjusted admission was only flat to slightly higher than a year earlier. This suggests that HCA is gaining greater control over its underlying cost base, even as the operating environment remains challenging. The progress is important because better cost control can help HCA offset inflation and protect profitability.
HCA’s investments in digital transformation, global capabilities and expanded shared services could support recurring productivity gains and reduce reliance on temporary cost-cutting measures. That matters as elective surgery remains pressured by affordability concerns, while changes in payer mix weigh on earnings.
If these initiatives consistently deliver productivity improvements, the resiliency program transitions from an emergency buffer into a durable margin driver. The ability to keep unit costs in check while maintaining volume growth could become an increasingly important contributor to HCA’s targeted 4-6% long-term adjusted EBITDA growth.
How Do Peers Compare?HCA is not alone in prioritizing operational efficiency. Medical peers such as Tenet Healthcare Corporation (THC - Free Report) and Universal Health Services, Inc. (UHS - Free Report) are also pursuing efficiency initiatives and expanding outpatient capabilities to drive growth and profitability.
Tenet Healthcare has strengthened profitability through operational discipline and a growing ambulatory-care platform. THC’s focus on efficiency, higher-acuity care and portfolio optimization strengthens earnings resilience and supports healthier margins.
Universal Health continues to emphasize disciplined cost management and operational efficiency across its hospital and behavioral-health businesses. UHS’ ability to control expenses while sustaining earnings growth makes its margin resilience an important factor for investors tracking healthcare operators.
HCA’s Price Performance, Valuation & EstimatesShares of HCA Healthcare have gained 3.8% over the past year compared with the industry's 12.8% growth over the same period.
Image Source: Zacks Investment Research
From a valuation standpoint, HCA trades at a forward price-to-earnings ratio of 13.44X, down from the industry average of 16.69X. HCA carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HCA’s 2026 earnings is pegged at $29.42 per share, implying a 4.3% jump from the year-ago period’s level.
Image Source: Zacks Investment Research
HCA currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Bank of Nova Scotia acquired a new position in shares of HCA Healthcare, Inc. (NYSE:HCA – Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 47,381 shares of the company’s stock, valued at approximately $18,473,000.
Other institutional investors have also modified their holdings of the company. BlackRock Inc. bought a new position in HCA Healthcare in the 2nd quarter worth about $5,069,974,000. State Street Corp boosted its position in shares of HCA Healthcare by 1.0% during the fourth quarter. State Street Corp now owns 7,566,643 shares of the company’s stock worth $3,532,563,000 after buying an additional 76,039 shares during the period. Capital World Investors increased its position in HCA Healthcare by 0.8% in the 4th quarter. Capital World Investors now owns 4,999,422 shares of the company’s stock valued at $2,334,040,000 after acquiring an additional 40,086 shares during the period. Geode Capital Management LLC boosted its position in HCA Healthcare by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 3,663,705 shares of the company’s stock worth $1,702,738,000 after acquiring an additional 13,565 shares during the period. Finally, Norges Bank acquired a new position in shares of HCA Healthcare during the fourth quarter valued at $1,262,513,000. Institutional investors own 62.73% of the company’s stock.
HCA Healthcare Stock Down 0.0% Shares of HCA Healthcare stock opened at $429.08 on Monday. HCA Healthcare, Inc. has a 12-month low of $353.99 and a 12-month high of $556.52. The firm has a market capitalization of $92.90 billion, a PE ratio of 14.36, a price-to-earnings-growth ratio of 1.49 and a beta of 1.10. The stock’s fifty day moving average is $397.16 and its 200-day moving average is $443.77.
HCA Healthcare (NYSE:HCA – Get Free Report) last posted its quarterly earnings data on Friday, July 24th. The company reported $7.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.56 by $0.03. The firm had revenue of $20.23 billion for the quarter, compared to the consensus estimate of $19.76 billion. HCA Healthcare had a negative return on equity of 244.79% and a net margin of 8.77%.The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $6.84 EPS. Analysts expect that HCA Healthcare, Inc. will post 29.47 EPS for the current year. HCA Healthcare Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 16th will be given a dividend of $0.78 per share. This represents a $3.12 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 16th. HCA Healthcare’s payout ratio is presently 10.45%.
Wall Street Analysts Forecast Growth Several equities analysts have commented on the stock. The Goldman Sachs Group lowered their target price on shares of HCA Healthcare from $558.00 to $485.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Weiss Ratings cut HCA Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 9th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of HCA Healthcare in a research note on Wednesday, July 15th. Stephens dropped their price target on shares of HCA Healthcare from $560.00 to $530.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Finally, Wells Fargo & Company lifted their price objective on shares of HCA Healthcare from $369.00 to $381.00 and gave the stock an “equal weight” rating in a research note on Monday, August 3rd. Fourteen equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $462.64.
View Our Latest Report on HCA
HCA Healthcare Company Profile (Free Report)
HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.
The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.
Featured Articles Five stocks we like better than HCA Healthcare VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA – Free Report).
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
B. Metzler seel. Sohn & Co. AG bought a new position in HCA Healthcare, Inc. (NYSE:HCA – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,563 shares of the company’s stock, valued at approximately $4,118,000.
Other hedge funds also recently bought and sold shares of the company. Palisade Asset Management LLC bought a new position in HCA Healthcare in the third quarter worth $26,000. Ares Financial Consulting LLC acquired a new stake in shares of HCA Healthcare during the 4th quarter worth approximately $31,000. Cedar Mountain Advisors LLC acquired a new position in HCA Healthcare in the first quarter valued at approximately $33,000. MCF Advisors LLC increased its holdings in HCA Healthcare by 213.0% in the fourth quarter. MCF Advisors LLC now owns 72 shares of the company’s stock valued at $34,000 after purchasing an additional 49 shares during the last quarter. Finally, MidFirst Bank acquired a new stake in shares of HCA Healthcare in the 2nd quarter valued at approximately $28,000. 62.73% of the stock is currently owned by institutional investors.
HCA Healthcare Price Performance NYSE:HCA opened at $429.08 on Friday. HCA Healthcare, Inc. has a 1 year low of $353.99 and a 1 year high of $556.52. The company has a market cap of $92.90 billion, a P/E ratio of 14.36, a P/E/G ratio of 1.41 and a beta of 1.10. The stock’s fifty day moving average price is $397.16 and its two-hundred day moving average price is $444.14.
HCA Healthcare (NYSE:HCA – Get Free Report) last announced its quarterly earnings results on Friday, July 24th. The company reported $7.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.56 by $0.03. HCA Healthcare had a net margin of 8.77% and a negative return on equity of 244.79%. The company had revenue of $20.23 billion for the quarter, compared to analysts’ expectations of $19.76 billion. During the same quarter in the previous year, the company earned $6.84 earnings per share. HCA Healthcare’s quarterly revenue was up 8.7% on a year-over-year basis. On average, analysts expect that HCA Healthcare, Inc. will post 29.47 earnings per share for the current fiscal year. HCA Healthcare Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 16th will be given a $0.78 dividend. This represents a $3.12 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 16th. HCA Healthcare’s payout ratio is currently 10.45%.
Analysts Set New Price Targets A number of analysts recently issued reports on the company. Cantor Fitzgerald lowered their target price on HCA Healthcare from $588.00 to $525.00 and set an “overweight” rating for the company in a research note on Tuesday, July 7th. Truist Financial reduced their target price on shares of HCA Healthcare from $535.00 to $495.00 and set a “buy” rating for the company in a research note on Monday, July 27th. JPMorgan Chase & Co. cut their price target on HCA Healthcare from $490.00 to $425.00 and set a “neutral” rating on the stock in a report on Thursday. Sanford C. Bernstein reiterated a “market perform” rating on shares of HCA Healthcare in a report on Wednesday, July 15th. Finally, Wall Street Zen cut shares of HCA Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Fourteen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, HCA Healthcare has an average rating of “Moderate Buy” and a consensus price target of $462.64.
View Our Latest Stock Report on HCA
HCA Healthcare Company Profile (Free Report)
HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.
The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.
Read More Five stocks we like better than HCA Healthcare Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
Advisors Capital Management LLC acquired a new stake in shares of HCA Healthcare, Inc. (NYSE:HCA – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 6,507 shares of the company’s stock, valued at approximately $2,537,000.
Several other institutional investors have also added to or reduced their stakes in HCA. BlackRock Inc. purchased a new position in HCA Healthcare during the 2nd quarter worth approximately $5,069,974,000. Norges Bank acquired a new position in shares of HCA Healthcare in the 4th quarter valued at about $1,262,513,000. Life Cycle Investment Partners Ltd acquired a new stake in HCA Healthcare during the fourth quarter worth about $374,037,000. Viking Global Investors LP lifted its holdings in HCA Healthcare by 58.5% in the second quarter. Viking Global Investors LP now owns 1,872,133 shares of the company’s stock valued at $717,214,000 after acquiring an additional 690,773 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its stake in shares of HCA Healthcare by 4,545.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 663,337 shares of the company’s stock worth $309,686,000 after purchasing an additional 649,058 shares during the period. Institutional investors and hedge funds own 62.73% of the company’s stock.
HCA Healthcare Stock Performance NYSE:HCA opened at $429.08 on Friday. HCA Healthcare, Inc. has a one year low of $353.99 and a one year high of $556.52. The business’s 50-day simple moving average is $397.16 and its 200 day simple moving average is $444.14. The stock has a market cap of $92.90 billion, a price-to-earnings ratio of 14.36, a price-to-earnings-growth ratio of 1.41 and a beta of 1.10.
HCA Healthcare (NYSE:HCA – Get Free Report) last announced its earnings results on Friday, July 24th. The company reported $7.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.56 by $0.03. The company had revenue of $20.23 billion for the quarter, compared to analyst estimates of $19.76 billion. HCA Healthcare had a negative return on equity of 244.79% and a net margin of 8.77%.HCA Healthcare’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the company posted $6.84 EPS. On average, equities research analysts predict that HCA Healthcare, Inc. will post 29.47 EPS for the current year. HCA Healthcare Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 16th will be issued a dividend of $0.78 per share. This represents a $3.12 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 16th. HCA Healthcare’s dividend payout ratio (DPR) is 10.45%.
Analysts Set New Price Targets A number of analysts have recently commented on HCA shares. Stephens cut their price objective on HCA Healthcare from $560.00 to $530.00 and set an “overweight” rating for the company in a research report on Monday, April 27th. Wall Street Zen downgraded shares of HCA Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Royal Bank Of Canada reissued an “outperform” rating and set a $435.00 target price on shares of HCA Healthcare in a research note on Monday, July 27th. Truist Financial lowered their price objective on HCA Healthcare from $535.00 to $495.00 and set a “buy” rating on the stock in a report on Monday, July 27th. Finally, Oppenheimer decreased their target price on HCA Healthcare from $520.00 to $485.00 and set an “outperform” rating on the stock in a research report on Monday, July 27th. Fourteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $462.64.
Get Our Latest Stock Report on HCA
About HCA Healthcare (Free Report)
HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.
The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.
Read More Five stocks we like better than HCA Healthcare Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates? Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA – Free Report).
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conferences:
September 9, 2026, at 10:15am ET at the Wells Fargo Healthcare Conference
September 15, 2026, at 1:50pm CT at the Jefferies Healthcare Conference
A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company’s website, www.hcahealthcare.com.
Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company’s website for the latest information.
About HCA Healthcare
Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 190 hospitals and approximately 2,600 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 19 states and the United Kingdom.
All references to “Company” and “HCA” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.
BlackRock Inc. acquired a new stake in shares of HCA Healthcare, Inc. (NYSE:HCA – Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 13,003,600 shares of the company’s stock, valued at approximately $5,069,974,000. BlackRock Inc. owned approximately 6.01% of HCA Healthcare at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in HCA. Palisade Asset Management LLC acquired a new position in shares of HCA Healthcare during the third quarter valued at about $26,000. Clearstead Trust LLC purchased a new position in shares of HCA Healthcare in the 2nd quarter valued at about $29,000. Ares Financial Consulting LLC purchased a new stake in HCA Healthcare in the 4th quarter worth $31,000. Cedar Mountain Advisors LLC acquired a new stake in shares of HCA Healthcare in the first quarter valued at about $33,000. Finally, JPL Wealth Management LLC acquired a new stake in shares of HCA Healthcare in the third quarter worth approximately $33,000. 62.73% of the stock is currently owned by hedge funds and other institutional investors.
HCA Healthcare Price Performance NYSE HCA opened at $412.27 on Wednesday. HCA Healthcare, Inc. has a 12 month low of $353.99 and a 12 month high of $556.52. The stock has a market capitalization of $89.26 billion, a P/E ratio of 13.80, a PEG ratio of 1.40 and a beta of 1.10. The firm’s 50-day moving average is $395.07 and its two-hundred day moving average is $445.35.
HCA Healthcare (NYSE:HCA – Get Free Report) last announced its earnings results on Friday, July 24th. The company reported $7.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.56 by $0.03. HCA Healthcare had a negative return on equity of 244.79% and a net margin of 8.77%.The company had revenue of $20.23 billion for the quarter, compared to analyst estimates of $19.76 billion. During the same quarter in the previous year, the company earned $6.84 earnings per share. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. As a group, analysts anticipate that HCA Healthcare, Inc. will post 29.47 EPS for the current year. HCA Healthcare Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 16th will be issued a $0.78 dividend. The ex-dividend date is Wednesday, September 16th. This represents a $3.12 dividend on an annualized basis and a dividend yield of 0.8%. HCA Healthcare’s payout ratio is 10.45%.
Analysts Set New Price Targets A number of equities research analysts have recently issued reports on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of HCA Healthcare in a report on Wednesday, July 15th. KeyCorp cut their price objective on shares of HCA Healthcare from $475.00 to $435.00 and set an “overweight” rating for the company in a report on Monday, July 27th. Truist Financial reduced their price objective on HCA Healthcare from $535.00 to $495.00 and set a “buy” rating on the stock in a research report on Monday, July 27th. Barclays dropped their target price on HCA Healthcare from $402.00 to $387.00 and set an “equal weight” rating for the company in a report on Monday, July 27th. Finally, Robert W. Baird dropped their price objective on shares of HCA Healthcare from $396.00 to $393.00 and set a “neutral” rating for the company in a report on Monday, July 27th. Fourteen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, HCA Healthcare has a consensus rating of “Moderate Buy” and an average price target of $465.59.
Get Our Latest Analysis on HCA Healthcare
About HCA Healthcare (Free Report)
HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.
The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.
See Also Five stocks we like better than HCA Healthcare The AI Boom Is Turning This Cable Maker Into a Stock to Watch A Star Investor Just Trimmed Amazon—Here’s What It means Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
On August 18, 2026, we conducted a discounted cash flow (DCF) analysis for HCA Healthcare Inc (HCA) in light of its recent price performance. The stock has expe
Assenagon Asset Management S.A. lessened its holdings in HCA Healthcare, Inc. (NYSE:HCA – Free Report) by 81.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,001 shares of the company’s stock after selling 63,779 shares during the period. Assenagon Asset Management S.A.’s holdings in HCA Healthcare were worth $5,849,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the stock. Brighton Jones LLC bought a new stake in shares of HCA Healthcare during the fourth quarter worth about $1,021,000. NewEdge Advisors LLC grew its stake in HCA Healthcare by 11.9% during the first quarter. NewEdge Advisors LLC now owns 3,859 shares of the company’s stock worth $1,334,000 after purchasing an additional 409 shares during the period. Sivia Capital Partners LLC increased its stake in shares of HCA Healthcare by 5.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 630 shares of the company’s stock valued at $241,000 after acquiring an additional 33 shares in the last quarter. Jump Financial LLC acquired a new position in shares of HCA Healthcare during the second quarter valued at about $2,073,000. Finally, Sei Investments Co. raised its stake in HCA Healthcare by 56.3% during the 2nd quarter. Sei Investments Co. now owns 136,589 shares of the company’s stock worth $52,328,000 after buying an additional 49,214 shares during the period. 62.73% of the stock is currently owned by institutional investors and hedge funds.
HCA Healthcare Price Performance Shares of NYSE HCA opened at $411.55 on Wednesday. The firm’s 50 day simple moving average is $390.75 and its two-hundred day simple moving average is $447.87. HCA Healthcare, Inc. has a one year low of $353.99 and a one year high of $556.52. The stock has a market capitalization of $89.10 billion, a P/E ratio of 13.78, a PEG ratio of 1.44 and a beta of 1.10.
HCA Healthcare (NYSE:HCA – Get Free Report) last announced its quarterly earnings data on Friday, July 24th. The company reported $7.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.56 by $0.03. HCA Healthcare had a negative return on equity of 244.79% and a net margin of 8.77%.The firm had revenue of $20.23 billion for the quarter, compared to analysts’ expectations of $19.76 billion. During the same period last year, the firm earned $6.84 earnings per share. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, equities analysts expect that HCA Healthcare, Inc. will post 29.45 earnings per share for the current fiscal year.
HCA Healthcare Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 16th will be paid a $0.78 dividend. The ex-dividend date of this dividend is Wednesday, September 16th. This represents a $3.12 annualized dividend and a dividend yield of 0.8%. HCA Healthcare’s dividend payout ratio (DPR) is presently 10.45%.
Trending Headlines about HCA Healthcare Here are the key news stories impacting HCA Healthcare this week:
Positive Sentiment: HCA’s Tennessee hospital appointed a new chief executive, providing a leadership update that could support local operations, although the move is unlikely to materially affect the broader company in the near term. HCA Tennessee hospital taps CEO Neutral Sentiment: HCA’s former CFO discussed the importance of partnerships in healthcare. The comments may reinforce the strategic value of collaboration and care-network development, but they do not indicate a new financial initiative or immediate change to HCA’s earnings outlook. HCA Healthcare’s former CFO on the role of partnerships in health Negative Sentiment: Healthcare workers at HCA hospitals are pushing for higher pay and increased staffing. Potential wage increases, labor-related disruptions and continued staffing shortages could raise operating costs and pressure margins, while criticism over staffing may create reputational risks. HCA workers push for higher pay and more staffing amid billions in profits Negative Sentiment: Zacks Research lowered EPS forecasts for HCA’s third and fourth quarters of 2026, multiple quarters in 2027 and the first two quarters of 2028. Its FY2027 estimate fell to $31.27 from $32.32, while the Q3 2026 forecast declined to $6.79 from $7.23. These broad estimate cuts are likely the main catalyst for the stock’s decrease because they imply softer-than-previously-expected earnings momentum. Analysts Set New Price Targets A number of analysts have commented on the stock. Sanford C. Bernstein restated a “market perform” rating on shares of HCA Healthcare in a research note on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft set a $476.00 price target on shares of HCA Healthcare in a report on Monday, July 27th. Jefferies Financial Group set a $450.00 target price on shares of HCA Healthcare in a research report on Tuesday, July 14th. Royal Bank Of Canada reiterated an “outperform” rating and set a $435.00 price objective on shares of HCA Healthcare in a research note on Monday, July 27th. Finally, KeyCorp decreased their target price on shares of HCA Healthcare from $475.00 to $435.00 and set an “overweight” rating on the stock in a report on Monday, July 27th. Fourteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $465.59.
Get Our Latest Report on HCA Healthcare
About HCA Healthcare (Free Report)
HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.
The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.
Featured Articles Five stocks we like better than HCA Healthcare Atlassian Just Pulled Off the Software Comeback Wall Street Wanted AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAssenagon Asset Management S.A. Invests $6.18 Million in Hello Group Inc. Sponsored ADR $MOMO
NEXT HEADLINE »Assenagon Asset Management S.A. Has $6.07 Million Stock Holdings in Badger Meter, Inc. $BMI
Deane Retirement Strategies Inc. acquired a new stake in shares of HCA Healthcare, Inc. (NYSE:HCA – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 12,298 shares of the company’s stock, valued at approximately $4,796,000. HCA Healthcare comprises 2.0% of Deane Retirement Strategies Inc.’s investment portfolio, making the stock its 22nd biggest holding.
Other institutional investors have also modified their holdings of the company. Norges Bank purchased a new stake in HCA Healthcare during the 4th quarter valued at $1,262,513,000. Life Cycle Investment Partners Ltd purchased a new position in shares of HCA Healthcare during the fourth quarter valued at approximately $374,037,000. Viking Global Investors LP grew its position in HCA Healthcare by 58.5% in the 2nd quarter. Viking Global Investors LP now owns 1,872,133 shares of the company’s stock valued at $717,214,000 after acquiring an additional 690,773 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in HCA Healthcare by 4,545.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 663,337 shares of the company’s stock valued at $309,686,000 after buying an additional 649,058 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of HCA Healthcare by 5,941.1% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 381,433 shares of the company’s stock valued at $180,509,000 after acquiring an additional 375,119 shares in the last quarter. 62.73% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades HCA has been the topic of a number of recent research reports. Cantor Fitzgerald dropped their price target on HCA Healthcare from $588.00 to $525.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 7th. Mizuho dropped their target price on shares of HCA Healthcare from $525.00 to $475.00 and set an “outperform” rating on the stock in a report on Tuesday, July 28th. Wells Fargo & Company upped their price target on shares of HCA Healthcare from $369.00 to $381.00 and gave the stock an “equal weight” rating in a research report on Monday, August 3rd. Deutsche Bank Aktiengesellschaft set a $476.00 target price on HCA Healthcare in a report on Monday, July 27th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $435.00 price target on shares of HCA Healthcare in a research report on Monday, July 27th. Fourteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $465.59.
Read Our Latest Stock Report on HCA
HCA Healthcare Price Performance HCA Healthcare stock opened at $412.80 on Monday. The business has a fifty day moving average price of $389.00 and a 200-day moving average price of $448.60. HCA Healthcare, Inc. has a 1-year low of $353.99 and a 1-year high of $556.52. The stock has a market capitalization of $89.37 billion, a price-to-earnings ratio of 13.82, a PEG ratio of 1.44 and a beta of 1.10.
HCA Healthcare (NYSE:HCA – Get Free Report) last issued its quarterly earnings results on Friday, July 24th. The company reported $7.59 earnings per share for the quarter, topping the consensus estimate of $7.56 by $0.03. The business had revenue of $20.23 billion during the quarter, compared to the consensus estimate of $19.76 billion. HCA Healthcare had a negative return on equity of 244.79% and a net margin of 8.77%.The company’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the company earned $6.84 earnings per share. On average, equities research analysts anticipate that HCA Healthcare, Inc. will post 29.45 earnings per share for the current fiscal year.
HCA Healthcare Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 16th will be issued a $0.78 dividend. The ex-dividend date of this dividend is Wednesday, September 16th. This represents a $3.12 dividend on an annualized basis and a dividend yield of 0.8%. HCA Healthcare’s dividend payout ratio (DPR) is currently 10.45%.
HCA Healthcare Company Profile (Free Report)
HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.
The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.
Recommended Stories Five stocks we like better than HCA Healthcare Albemarle’s Blowout Quarter Shows Why Lithium Still Matters Can DICK’S Turn Foot Locker Into a Winner? Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINESPDR Portfolio Short Term Corporate Bond ETF $SPSB Shares Purchased by Capital Wealth Management LLC
NEXT HEADLINE »Ferguson Shapiro LLC Acquires Shares of 87,512 Freedom 100 Emerging Markets ETF $FRDM
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company's payer mix, which impacted revenue by approximately $400 million in the quarter.
On this news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA) today announced that Michael Schlosser, M.D., MBA, senior vice president and chief transformation officer, has been appointed executive vice president and chief clinical officer, effective Sept. 1, 2026. Also, effective Sept. 1, Charles Gressle, president of HCA Healthcare's East Florida Division, has been appointed president of HCA Healthcare's new Ambulatory Operations Group. Dr. Schlosser will succeed Dr. Michael Cuffe, who a.
Lending support to his choice, Fortinet, on July 29, reported better-than-expected second-quarter financial results and issued third-quarter guidance above estimates.
CME Group Inc. (NASDAQ:CME) is “very good,” Cramer said. “I’ve always liked the companies that are involved with trading because they have monopolies or at least duopolies.”
As per the recent news, CME Group reported record July ADV of 27 million contracts, up 23% year-over-year.
Cramer said Alcoa Corporation (NYSE:AA) is “better than it used to be, but it’s still a commodity.”
On the earnings front, Alcoa reported mixed second-quarter financial results on July 16.
As per the recent news, Denison Mines, on July 28, announced the completion of site preparation activities and commencement of full-scale construction at the Phoenix In-Situ Recovery uranium mine.
HCA Healthcare, on July 24, released second-quarter 2026 revenues of $20.23 billion, representing an 8.7% year-over-year increase, beating the consensus estimate of $19.40 billion.
Shelton, Connecticut-based Hubbell Incorporated (NYSE:HUBB) is a “basic, great American company. You have to hold on to it any time it goes down,” Cramer said.
Hubbell, on July 28, posted better-than-expected earnings for the second quarter.
Rocket Lab, on Tuesday, said it secured a $397 million contract from the U.S. Space Force to build, launch and operate satellites for its Space-Based Airborne Moving Target Indicator (SB-AMTI) program.
Price ActionPhoto via Shutterstock
Market News and Data brought to you by Benzinga APIs
If you purchased or acquired stock in HCA and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) --
What’s Happening?
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against HCA Healthcare, Inc. (“HCA” or the “Company”) (NYSE:HCA) on behalf of HCA stockholders. Our investigation concerns whether HCA has violated the federal securities laws and/or engaged in other unlawful business practices. What are the Investigation Details?
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company's payer mix, which impacted revenue by approximately $400 million in the quarter.On this news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026. What are my Next Steps?
If you purchased or otherwise acquired HCA shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. (“HCA” or the “Company”) (NYSE: HCA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company’s payer mix, which impacted revenue by approximately $400 million in the quarter.
On this news, HCA’s stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of HCA Healthcare, Inc. (“HCA Healthcare” or the “Company”) (NYSE: HCA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On July 14, 2026, HCA Healthcare issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA Healthcare sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company’s payer mix, driven by an increase in uninsured volume—primarily due to patients who had lost coverage on health insurance exchanges—which impacted revenue by approximately $400 million in the quarter. The Company lowered its forecast for 2026 earnings to between $28.70 and $30.50 a share and narrowed its revenue target to $77 billion to $79.5 billion from a prior $76.5 billion to $80 billion range. Adjusted earnings before interest, taxes, depreciation and amortization are targeted at between $15.4 billion and $16.1 billion, where HCA Healthcare previously anticipated $15.55 billion to $16.45 billion.
On this news, HCA Healthcare’s stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws. Click here to learn more about securities class actions.
If you purchased or otherwise acquired HCA Healthcare securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT THE INVESTIGATION]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260803791643/en/
NEW YORK--(BUSINESS WIRE)---- $HCA #classaction--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of HCA Healthcare, Inc. (“HCA Healthcare” or the “Company”) (NYSE: HCA) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On July 14, 2026, HCA Healthcare issued a press release reporting its preliminary financial and operat.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc.("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company's payer mix, which impacted revenue by approximately $400 million in the quarter.
On this news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. (“HCA” or the “Company”) (NYSE: HCA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company’s payer mix, which impacted revenue by approximately $400 million in the quarter.
On this news, HCA’s stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
U.S. Fund A Shares (without sales charge) posted a return of -0.04% in second quarter of 2026. Leading contributors in the First Eagle U.S. Fund this quarter included Alphabet Inc. Class C, Texas Instruments, Elevance Health, Bank of New York Mellon Corporation and Cummins. The leading detractors in the quarter were First Eagle Global Real Assets Cayman Fund Ltd. USD, HCA Healthcare, Charter Communications, Inc. Class A, Exxon Mobil and Salesforce.
HCA Healthcare Inc. (NYSE:HCA) on Friday posted upbeat second-quarter earnings.
The company posted second-quarter 2026 revenues of $20.23 billion, representing an 8.7% year-over-year increase, beating the consensus estimate of $19.40 billion. The company reported adjusted earnings of $7.59, up from $6.84 a year ago, surpassing the Wall Street estimates of $7.02.
HCA Healthcare reaffirmed fiscal 2026 earnings guidance of $28.70-$30.50 per share compared to the consensus of $29.70. The company expects 2026 sales of $77 billion-$79.50 billion versus the consensus of $78.457 billion.
HCA Healthcare shares gained 2.34% to trade at $391.35 on Monday.
These analysts made changes to their price targets on HCA Healthcare following earnings announcement.
Considering buying HCA stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
HCA Healthcare (NYSE:HCA) said its second-quarter performance reflected solid demand in several service lines and 11% growth in diluted earnings per share, but the company faced increased financial pressure as patients losing health insurance exchange coverage shifted largely into the uninsured population.
Chief Executive Officer Sam Hazen said the expiration of enhanced premium tax credits at the end of 2025 led more patients to lose exchange coverage than the company had anticipated. While HCA expected some individuals to move to other coverage options, Hazen said patients instead migrated “almost one for one” to uninsured status while continuing to require hospital care.
“The effects, as expected, were that many people became uninsured and still needed emergency care from hospitals,” Hazen said. He added that the impact in the first half of 2026 was greater than the company’s original estimates.
Payer Mix Shift Drives Updated Outlook Same-facility equivalent admissions among patients covered through health insurance exchanges declined 15% in the second quarter and year to date, according to Chief Financial Officer Mike Marks. Equivalent admissions among insured patients excluding exchange plans increased 3.2% in the second quarter, while total uninsured equivalent admissions rose 15%.
Marks said the exchange-related payer mix shift created an approximately $400 million unfavorable impact on adjusted EBITDA in the second quarter. That figure included about $75 million tied to a higher estimate of the first-quarter exchange impact.
The company now expects the full-year adjusted EBITDA impact from health insurance exchange changes to range from negative $1 billion to negative $1.2 billion. Marks said the updated outlook reflects the company’s conclusion that nearly all patients losing exchange coverage are becoming uninsured, compared with its prior assumption that 80% to 85% would do so. HCA also said its original expectation that uninsured patients would use fewer healthcare services did not materialize.
Three divisions—Gulf Coast, North Florida and South Atlantic—accounted for about half of the companywide exchange-related impact. Hazen said exchange adjusted admissions in those divisions declined between 25% and 28% in the first half.
HCA revised its full-year 2026 guidance to:
Revenue of $77 billion to $79.5 billion. Adjusted EBITDA of $15.4 billion to $16.1 billion. Net income attributable to HCA Healthcare of $6.3 billion to $6.7 billion. Diluted earnings per share of $28.70 to $30.50. Marks said the revised outlook is more consistent with HCA’s long-term adjusted EBITDA growth target of 4% to 6%, following moderation from the company’s 2025 growth rate and its initial 2026 assumptions.
Medicaid Programs Offset Pressure in the Quarter The company recognized approximately $400 million of incremental net benefit from Medicaid supplemental payment programs during the second quarter. That included a $540 million incremental net benefit related to a recently approved Florida program covering the period from Oct. 1, 2024, through June 30, 2026, or 21 months.
The Florida benefit was partly offset by retroactive payments received in the second quarter of 2025. HCA’s annual guidance assumes a net Medicaid supplemental-payment benefit of $300 million to $500 million, but Marks said the outlook implies a $100 million to $300 million headwind in the second half because prior program approvals and retroactive payments are expected to exceed the incremental benefit from the Florida program.
Hazen described Medicaid supplemental programs as important to supporting access to care for Medicaid patients, particularly as hospitals provide more uncompensated care to uninsured patients.
Demand Growth Continues, Though Surgeries Decline Same-facility admissions increased 2.5% in the second quarter, while equivalent admissions rose 2.7%. Emergency room visits increased 3.6%, with cardiac procedures and rehabilitation volumes also contributing to demand.
However, inpatient surgeries declined 2.3% and outpatient surgeries fell 3.4%. Hazen attributed much of the decline to reduced demand for elective procedures, including patients previously covered through exchange plans. He also cited physician feedback regarding affordability pressures affecting patients and the effect of Medicare inpatient rule changes that have shifted some cases from inpatient to outpatient settings.
Emergency inpatient surgeries, which account for about two-thirds of HCA’s inpatient surgical cases, increased 2% year over year through the first six months. By contrast, elective inpatient surgeries were down 6% this year, compared with a 2% decline in the prior year.
Despite the surgical weakness, Hazen said the company remains encouraged by demand and continues to expect long-term demand growth of 2% to 3%, supported by population growth and market trends in its communities.
Capital Investment and Cost Initiatives HCA has approved more than $7 billion of capital spending expected to come online over the next three years. The investments include 1,000 to 1,200 additional inpatient beds, new hospitals in certain markets, and additional outpatient facilities.
Hazen said the company had approximately 42,000 beds currently in operation, up from roughly 37,000 at the end of 2018. Occupancy increased to 75% from 71% over that period. HCA also had 5% more outpatient sites of care in the second quarter than a year earlier and expects another 250 to 300 outpatient facilities in its capital or acquisition pipeline to open later this year or early next year.
The company spent $1.2 billion on capital expenditures during the quarter, repurchased $2.1 billion of shares and paid $171 million in dividends. Cash flow from operations was $2.3 billion, down 45% year over year, primarily because of the timing of Florida Medicaid supplemental-payment cash flows and the prior-year deferral of federal income tax payments.
HCA maintained its planned 2026 capital expenditure range of $5 billion to $5.5 billion and said it currently expects to complete most of its existing share-repurchase authorization, subject to market conditions and other factors.
On costs, Marks said same-facility cost per equivalent admission, including the effect of Medicaid supplemental payment programs, was essentially flat from a year earlier and improved 1.4% sequentially. He said HCA’s financial resiliency program—which includes digital transformation, global capabilities and expanded shared services—is intended to produce multiyear efficiency benefits. Professional fees remained elevated, rising about 8.5% year over year in the quarter, primarily due to anesthesia and radiology costs.
About HCA Healthcare (NYSE:HCA) HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.
The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.
Diluted Earnings Per Share Growth: 11% in the quarter and year-to-date.Admissions Growth: Increased 2.5% in the second quarter.Equivalent Admissions Growth: In
The company reported adjusted earnings of $7.59, up from $6.84 a year ago, surpassing the Wall Street estimates of $7.02.
Adjusted EBITDA reached $4.027 billion, compared to $3.849 billion a year ago.
Admissions Growth And Medicaid Payments Support ResultsThe company also experienced positive factors including increased benefit from Medicaid Supplemental Payment Programs, growth in admissions, equivalent admissions and ER visits, and improved expense results.
Same facility admissions increased 2.5% and same facility equivalent admissions increased 2.7%. Same facility emergency room visits increased 3.6%.
Same facility inpatient surgeries declined 2.3%, and outpatient surgeries declined 3.4% in the quarter. Same facility revenue per equivalent admission increased 6.4%.
Surgical Volume And Payer Mix Weigh On PerformanceAs announced earlier, during the second quarter, the company experienced a payer mix shift driven by an increase in uninsured volume, primarily due to patients who lost coverage on the health insurance exchanges.
The company estimates this payer mix shift had an unfavorable impact on income before income taxes of approximately $400 million during the second quarter.
The amount includes an increase of approximately $75 million related to the company’s previous estimate of the first quarter health insurance exchange impact.
In addition, to a lesser degree, HCA Healthcare experienced a service mix shift primarily related to a decline in surgical volume.
HCA Reaffirms Full-Year 2026 OutlookHCA Healthcare reaffirmed fiscal 2026 earnings guidance of $28.70-$30.50 per share compared to the consensus of $29.70.
The company expects 2026 sales of $77 billion-$79.50 billion versus the consensus of $78.457 billion.
HCA Stock Price Activity: HCA Healthcare shares were up 3.62% at $390.12 at the time of publication on Friday, according to Benzinga Pro data.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
Healthcare Added 35,200 Jobs—3 Stocks Positioned to BenefitHCA Healthcare NYSE: HCA said its second-quarter performance reflected solid demand in several service lines and 11% growth in diluted earnings per share, but the company faced increased financial pressure as patients losing health insurance exchange coverage shifted largely into the uninsured population.
Chief Executive Officer Sam Hazen said the expiration of enhanced premium tax credits at the end of 2025 led more patients to lose exchange coverage than the company had anticipated. While HCA expected some individuals to move to other coverage options, Hazen said patients instead migrated “almost one for one” to uninsured status while continuing to require hospital care.
Get HCA Healthcare alerts:
The Aging of America Could Make HCA Healthcare a Long-Term Winner“The effects, as expected, were that many people became uninsured and still needed emergency care from hospitals,” Hazen said. He added that the impact in the first half of 2026 was greater than the company’s original estimates.
Payer Mix Shift Drives Updated Outlook Same-facility equivalent admissions among patients covered through health insurance exchanges declined 15% in the second quarter and year to date, according to Chief Financial Officer Mike Marks. Equivalent admissions among insured patients excluding exchange plans increased 3.2% in the second quarter, while total uninsured equivalent admissions rose 15%.
This ETF Is Proof That the Healthcare Rebound Is RealMarks said the exchange-related payer mix shift created an approximately $400 million unfavorable impact on adjusted EBITDA in the second quarter. That figure included about $75 million tied to a higher estimate of the first-quarter exchange impact.
The company now expects the full-year adjusted EBITDA impact from health insurance exchange changes to range from negative $1 billion to negative $1.2 billion. Marks said the updated outlook reflects the company’s conclusion that nearly all patients losing exchange coverage are becoming uninsured, compared with its prior assumption that 80% to 85% would do so. HCA also said its original expectation that uninsured patients would use fewer healthcare services did not materialize.
Three divisions—Gulf Coast, North Florida and South Atlantic—accounted for about half of the companywide exchange-related impact. Hazen said exchange adjusted admissions in those divisions declined between 25% and 28% in the first half.
HCA revised its full-year 2026 guidance to:
Revenue of $77 billion to $79.5 billion. Adjusted EBITDA of $15.4 billion to $16.1 billion. Net income attributable to HCA Healthcare of $6.3 billion to $6.7 billion. Diluted earnings per share of $28.70 to $30.50. Marks said the revised outlook is more consistent with HCA’s long-term adjusted EBITDA growth target of 4% to 6%, following moderation from the company’s 2025 growth rate and its initial 2026 assumptions.
Medicaid Programs Offset Pressure in the Quarter The company recognized approximately $400 million of incremental net benefit from Medicaid supplemental payment programs during the second quarter. That included a $540 million incremental net benefit related to a recently approved Florida program covering the period from Oct. 1, 2024, through June 30, 2026, or 21 months.
The Florida benefit was partly offset by retroactive payments received in the second quarter of 2025. HCA’s annual guidance assumes a net Medicaid supplemental-payment benefit of $300 million to $500 million, but Marks said the outlook implies a $100 million to $300 million headwind in the second half because prior program approvals and retroactive payments are expected to exceed the incremental benefit from the Florida program.
Hazen described Medicaid supplemental programs as important to supporting access to care for Medicaid patients, particularly as hospitals provide more uncompensated care to uninsured patients.
Demand Growth Continues, Though Surgeries Decline Same-facility admissions increased 2.5% in the second quarter, while equivalent admissions rose 2.7%. Emergency room visits increased 3.6%, with cardiac procedures and rehabilitation volumes also contributing to demand.
However, inpatient surgeries declined 2.3% and outpatient surgeries fell 3.4%. Hazen attributed much of the decline to reduced demand for elective procedures, including patients previously covered through exchange plans. He also cited physician feedback regarding affordability pressures affecting patients and the effect of Medicare inpatient rule changes that have shifted some cases from inpatient to outpatient settings.
Emergency inpatient surgeries, which account for about two-thirds of HCA’s inpatient surgical cases, increased 2% year over year through the first six months. By contrast, elective inpatient surgeries were down 6% this year, compared with a 2% decline in the prior year.
Despite the surgical weakness, Hazen said the company remains encouraged by demand and continues to expect long-term demand growth of 2% to 3%, supported by population growth and market trends in its communities.
Capital Investment and Cost Initiatives HCA has approved more than $7 billion of capital spending expected to come online over the next three years. The investments include 1,000 to 1,200 additional inpatient beds, new hospitals in certain markets, and additional outpatient facilities.
Hazen said the company had approximately 42,000 beds currently in operation, up from roughly 37,000 at the end of 2018. Occupancy increased to 75% from 71% over that period. HCA also had 5% more outpatient sites of care in the second quarter than a year earlier and expects another 250 to 300 outpatient facilities in its capital or acquisition pipeline to open later this year or early next year.
The company spent $1.2 billion on capital expenditures during the quarter, repurchased $2.1 billion of shares and paid $171 million in dividends. Cash flow from operations was $2.3 billion, down 45% year over year, primarily because of the timing of Florida Medicaid supplemental-payment cash flows and the prior-year deferral of federal income tax payments.
HCA maintained its planned 2026 capital expenditure range of $5 billion to $5.5 billion and said it currently expects to complete most of its existing share-repurchase authorization, subject to market conditions and other factors.
On costs, Marks said same-facility cost per equivalent admission, including the effect of Medicaid supplemental payment programs, was essentially flat from a year earlier and improved 1.4% sequentially. He said HCA’s financial resiliency program—which includes digital transformation, global capabilities and expanded shared services—is intended to produce multiyear efficiency benefits. Professional fees remained elevated, rising about 8.5% year over year in the quarter, primarily due to anesthesia and radiology costs.
About HCA Healthcare (NYSE:HCA)HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.
The company's core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA's services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in HCA Healthcare Right Now?Before you consider HCA Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HCA Healthcare wasn't on the list.
While HCA Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Key Takeaways HCA posted Q2 adjusted EPS of $7.59, beating estimates as revenues climbed 8.7% year over year.HCA saw higher admissions, revenue per admission and ER visits, while inpatient and outpatient surgeries fell.HCA narrowed revenue guidance but reduced adjusted EBITDA, net income and diluted EPS forecasts for 2026. HCA Healthcare, Inc. (HCA - Free Report) reported second-quarter 2026 adjusted earnings per share (EPS) of $7.59, which beat the Zacks Consensus Estimate of $7.57. The bottom line advanced 11% year over year.
Revenues rose 8.7% year over year to $20.2 billion. The top line was in line with the Zacks Consensus Estimate.
The quarterly results benefited from higher same-facility admissions, strong revenue per equivalent admission and solid emergency room visit growth. However, declining inpatient and outpatient surgeries, along with elevated operating expenses, partially offset these positives.
HCA Healthcare, Inc. Price, Consensus and EPS SurpriseHCA’s Q2 DetailsSame-facility equivalent admissions grew 2.7% year over year in the second quarter, beating our growth estimate of 2%. Meanwhile, same-facility admissions increased 2.5%, also surpassing our growth estimate of 1.8%.
Same-facility revenue per equivalent admission rose 6.4% year over year but came in higher than our growth estimate of 4.2%.
Same-facility inpatient surgeries fell 2.3% year over year, while same-facility outpatient surgeries dipped 3.4%. Same-facility emergency room visits inched up 3.6% year over year in the quarter.
Salaries and benefits, supplies and other operating expenses increased 9.8% year over year to $16.2 billion. The metric came in higher than our estimate of $15.4 billion.
Adjusted EBITDA of $4 billion advanced 4.6% year over year, which marginally beat our estimate of $3.9 billion.
HCA Healthcare operated 190 hospitals and roughly 2,600 ambulatory sites of care across 19 states and the United Kingdom as of June 30, 2026.
HCA’s Q2 Financial UpdateHCA Healthcare exited the second quarter with approximately $1 billion in cash and cash equivalents, down 2.6% from the 2025-end level. It had approximately $3.1 billion of available capacity under its credit facilities at the end of the reported quarter.
Total assets of $63.3 billion increased 4.2% from 2025-end figure.
Long-term debt, excluding debt issuance costs and discounts, was $43.5 billion, up 4.4% from the figure as of Dec. 31, 2025. Short-term borrowings and long-term debt due within a year totaled $6.3 billion.
Capital expenditures, excluding acquisitions, amounted to $1.2 billion during the quarter.
HCA’s Cash FlowCash flows from operating activities declined 44.5% year over year to $2.3 billion in the second quarter of 2026.
HCA Healthcare’s Capital Deployment UpdateHCA bought back shares worth approximately $2.1 billion in the second quarter. It had about $7.2 billion remaining under its share repurchase authorization as of June 30, 2026. The board also declared a quarterly cash dividend of 78 cents per share, payable on Sept. 30, 2026, to shareholders of record as of Sept. 16, 2026.
HCA Revises 2026 GuidanceRevenue guidance has been revised to $77.0-$79.5 billion from the previous $76.5-$80.0 billion, raising the lower end by $0.5 billion and lowering the upper end by $0.5 billion. The midpoint of the revised range implies 3.5% growth from the 2025 reported figure.
Adjusted EBITDA guidance has been narrowed to $15.4-$16.1 billion from $15.55-$16.45 billion. The midpoint suggests about 1.2% growth from the 2025 reported figure.
Net income guidance was lowered to $6.3-$6.7 billion from $6.495-$7.035 billion. The midpoint implies about a 4.2% decline from the 2025 reported figure.
Diluted EPS guidance was lowered to $28.70-$30.50 from $29.10-$31.50. The midpoint implies about 4.5% growth from the 2025 reported figure.
Capital expenditures, excluding acquisitions, remain projected in the range of $5.0-$5.5 billion.
HCA’s Zacks Rank & Key PicksHCA currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader Medical space are Charles River Laboratories International, Inc. (CRL - Free Report) , CVS Health Corporation (CVS - Free Report) and Cencora, Inc. (COR - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Charles River is set to report second-quarter 2026 results on Aug. 5, before the market closes. The Zacks Consensus Estimate for earnings is pegged at $2.72 per share, which has witnessed one upward revision and one downward revision over the past 30 days. The company beat on earnings in each of the trailing four quarters, with the average surprise being 9.3%. The consensus estimate for Charles River’s second-quarter revenues is pinned at $970.77 million.
CVS Health is set to report second-quarter 2026 results on Aug. 5, before the market closes. The Zacks Consensus Estimate for earnings is pegged at $1.87 per share, indicating a 3.3% year-over-year increase. The company beat on earnings in each of the trailing four quarters, with the average surprise being 16.8%. The consensus estimate for CVS Health’s second-quarter revenues is pinned at $100.18 billion, indicating a 1.3% year-over-year increase.
Cencora is set to report second-quarter 2026 results on Aug. 5, before the market closes. The Zacks Consensus Estimate for earnings is pegged at $4.37 per share, indicating a 9.3% year-over-year increase. The company beat on earnings in three of the trailing four quarters and missed once, with the average surprise being 1.6%. The consensus estimate for Cencora’s second-quarter revenues is pinned at $84.89 billion, indicating a 5.2% year-over-year increase.
HCA Healthcare (HCA - Free Report) came out with quarterly earnings of $7.59 per share, beating the Zacks Consensus Estimate of $7.57 per share. This compares to earnings of $6.84 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +0.26%. A quarter ago, it was expected that this hospital operator would post earnings of $7.17 per share when it actually produced earnings of $7.15, delivering a surprise of -0.28%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
HCA, which belongs to the Zacks Medical Services industry, posted revenues of $20.23 billion for the quarter ended June 2026, in line with the Zacks Consensus Estimate. This compares to year-ago revenues of $18.61 billion. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
HCA shares have lost about 19.4% since the beginning of the year versus the S&P 500's gain of 8.2%.
What's Next for HCA?While HCA has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for HCA was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $7.13 on $19.73 billion in revenues for the coming quarter and $29.19 on $78.51 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Teladoc (TDOC - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on July 29.
This telehealth services provider is expected to post quarterly loss of $0.24 per share in its upcoming report, which represents a year-over-year change of -26.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Teladoc's revenues are expected to be $614.69 million, down 2.7% from the year-ago quarter.
HCA Healthcare (HCA - Free Report) reported $20.23 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 8.7%. EPS of $7.59 for the same period compares to $6.84 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $20.23 billion, representing no surprise. The company delivered an EPS surprise of +0.26%, with the consensus EPS estimate being $7.57.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how HCA performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue per Equivalent Admission: $19,370.00 versus $18,771.14 estimated by five analysts on average.Equivalent Admissions: 1.04 billion versus the five-analyst average estimate of 1.04 billion.Admissions: 579.56 million versus the three-analyst average estimate of 579.01 million.Patient Days: 2,690.92 Days compared to the 2,713.59 Days average estimate based on two analysts.Average Length of Stay: 5 versus 5 estimated by two analysts on average.Number of hospitals: 190 versus 189 estimated by two analysts on average.Inpatient Revenue per Admission: $22,524.00 compared to the $20,251.40 average estimate based on two analysts.Equivalent Patient Days: 4.85 million versus 4.9 million estimated by two analysts on average.Licensed Beds at End of Period: 50,550 versus 50,729 estimated by two analysts on average.Number of freestanding outpatient surgery centers: 118 versus the two-analyst average estimate of 119.View all Key Company Metrics for HCA here>>>
Shares of HCA have returned -2.7% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2026. The Company's financial and operating results, as well as its updated guidance and key assumptions, are consistent with its July 14, 2026 second quarter preview. Key second quarter metrics (all percentage changes compare 2Q 2026 to 2Q 2025 unless otherwise noted): Revenues increased 8.7 percent to $20.230 billion Net income attributable.
[url="]HCA Healthcare, Inc.[/url] (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2026. The Company's finan
HCA Healthcare Inc (HCA) released its 8-K filing on July 24, 2026, detailing its financial results for the second quarter ended June 30, 2026. As the largest he
, /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by HCA Healthcare, Inc. (NYSE: HCA) on behalf of investors who purchased or acquired HCA Healthcare, Inc. securities and experienced significant financial losses.
HCA Announces Disappointing Financial Results
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the company's payer mix, which impacted revenue by approximately $400 million in the quarter.
HCA's Stock Drops Over 6%
Following the news of HCA's poor financial results, HCA Healthcare, Inc.'s stock price fell over 6%.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired HCA Healthcare, Inc. securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/hca-hca-healthcare-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=hca&mktm=PR
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.
CONTACT:
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company's payer mix, which impacted revenue by approximately $400 million in the quarter.
On this news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
LOS ANGELES, July 22, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises HCA Healthcare, Inc., (“HCA" or the "Company") (NYSE: HCA) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or join the case via https://portnoylaw.com/hca-healthcare-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On July 14, 2026, HCA Healthcare published a press release outlining its preliminary operational and financial performance for the second quarter of 2026. Within the release, the enterprise significantly downgraded its full-year 2026 earnings outlook, attributing the reduction to an adverse shift in its payer breakdown. This trend was spurred by a surge in uninsured patient visits—largely stemming from individuals losing coverage through health insurance marketplaces—which erased roughly $400 million in quarterly revenue. Consequently, HCA revised its full-year earnings forecast downward to a range of $28.70 to $30.50 per share, while tightening its revenue guidance to between $77 billion and $79.5 billion (compared to its previous projection of $76.5 billion to $80 billion). Adjusted EBITDA expectations were also scaled back to $15.4 billion–$16.1 billion, down from the prior target of $15.55 billion–$16.45 billion.
Following these disclosures, HCA Healthcare’s equity value dropped by $27.14 per share, or 6.95%, settling at $363.60 at the close of trading on July 14, 2026.
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar [email protected]
310-692-8883
www.portnoylaw.com
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In HCA To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in HCA and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.
Click here to participate in the action.
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) --
What’s Happening:
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against HCA Healthcare, Inc. (“HCA” or the “Company”) (NYSE:HCA) on behalf of HCA stockholders. Our investigation concerns whether HCA has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company's payer mix, which impacted revenue by approximately $400 million in the quarter.
On this news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
Next Steps:
If you purchased or otherwise acquired HCA shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. (“HCA” or the “Company”) (NYSE: HCA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company’s payer mix, which impacted revenue by approximately $400 million in the quarter.
On this news, HCA’s stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
RADNOR, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by HCA Healthcare, Inc. (NYSE: HCA) on behalf of investors who purchased or acquired HCA Healthcare, Inc. securities and experienced significant financial losses.
HCA Announces Disappointing Financial Results
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the company's payer mix, which impacted revenue by approximately $400 million in the quarter.
HCA’s Stock Drops Over 6%
Following the news of HCA’s poor financial results, HCA Healthcare, Inc.’s stock price fell over 6%.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired HCA Healthcare, Inc. securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/hca-hca-healthcare-inc-investigation?utm_campaign=hc?utm_source=Globe&utm_medium=pressrelease&utm_campaign=hca&mktm=PR
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.
CONTACT:
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453 [email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against HCA Healthcare, Inc. (“HCA Healthcare” or the “Company”) (NYSE: HCA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On July 14, 2026, HCA Healthcare issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA Healthcare sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company’s payer mix, driven by an increase in uninsured volume—primarily due to patients who had lost coverage on health insurance exchanges—which impacted revenue by approximately $400 million in the quarter. The Company lowered its forecast for 2026 earnings to between $28.70 and $30.50 a share and narrowed its revenue target to $77 billion to $79.5 billion from a prior $76.5 billion to $80 billion range. Adjusted earnings before interest, taxes, depreciation and amortization are targeted at between $15.4 billion and $16.1 billion, where HCA Healthcare previously anticipated $15.55 billion to $16.45 billion.
On this news, HCA Healthcare’s stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired HCA Healthcare securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by HCA Healthcare, Inc. (NYSE: HCA) on behalf of investors who purchased or acquired HCA Healthcare, Inc. securities and experienced significant financial losses.
HCA Announces Disappointing Financial Results
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the company's payer mix, which impacted revenue by approximately $400 million in the quarter.
HCA’s Stock Drops Over 6%
Following the news of HCA’s poor financial results, HCA Healthcare, Inc.’s stock price fell over 6%.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired HCA Healthcare, Inc. securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/hca-hca-healthcare-inc-investigation?utm_campaign=hc?utm_source=Businesswire&utm_medium=pressrelease&utm_campaign=hca&mktm=PR
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Key Takeaways HCA reports Q2 2026 results July 24, with consensus EPS of $7.41 on revenue of $19.92 billion.HCA is expected to see higher admissions and revenue per admission, supporting year-over-year growth.HCA faces pressure from higher expenses, shorter stays and fewer outpatient surgery cases. Hospital operator HCA Healthcare, Inc. (HCA - Free Report) is set to report second-quarter 2026 results on July 24, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $7.41 per shareon revenues of $19.92 billion.
The second-quarter earnings estimate has witnessed one upward revision against no movement in the opposite direction over the past 30 days. The bottom-line projection indicates year-over-year growth of 8.3%. Also, the Zacks Consensus Estimate for quarterly revenues implies a year-over-year increase of 7.1%.
Image Source: Zacks Investment Research
For 2026, the Zacks Consensus Estimate for HCA Healthcare’s revenues is pegged at $78.57 billion, implying a rise of 3.9% year over year. The consensus mark for 2026 EPS is pegged at $29.87, implying an increase of 5.9% year over year.
HCA Healthcare’s earnings beat estimates in three of the last four quarters and missed once, with the average surprise being 10.6%. This is depicted in the figure below.
Q2 Earnings Whispers for HCAOur proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.
HCA has an Earnings ESP of +2.41% and a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
What’s Shaping HCA Healthcare’s Q2 Results?The Zacks Consensus Estimate for HCA Healthcare’s second-quarter equivalent admissions indicates 2.2% year-over-year growth, whereas our model estimate suggests a 1.7% jump. The consensus mark for revenue per equivalent admission signals a 2.7% rise from a year ago, while we expect 2.1% growth.
The consensus estimate for occupancy is pegged at 72.8%, up from 72% a year ago. The Zacks Consensus Estimate for equivalent patient days indicates a 1.9% year-over-year increase.
While these factors are likely to have positioned HCA Healthcare for growth from the year-ago quarter, rising expenses, lower average length of stay and outpatient surgery cases make an earnings beat uncertain.
Our model estimate for second-quarter total operating expenses indicates a 4.4% increase from a year ago, due to higher salaries & benefits, supply costs and other operating expenses. We expect supply costs to jump 3.3% in the to-be-reported quarter.
The Zacks Consensus Estimate for average length of stay indicates a 0.8% decline from the year-ago period. Moreover, both the consensus estimate and our model estimate for outpatient surgery cases imply a 0.3% fall from a year ago.
Stocks That Warrant a LookWhile an earnings beat looks uncertain for HCA Healthcare, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around:
ProMIS Neurosciences, Inc. (PMN - Free Report) has an Earnings ESP of +13.30% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for ProMIS’ bottom line for the to-be-reported quarter of a loss of $1.45 indicates 80% year-over-year improvement. It has witnessed one upward revision against no downward movement over the past 60 days.
Alcon Inc. (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank of 2.
The Zacks Consensus Estimate for Alcon’s bottom line for the to-be-reported quarter indicates a 1.3% increase from a year ago. The company’s earnings beat estimates in three of the trailing four quarters and missed once, with an average surprise of 3.7%. The consensus estimate for ALC’s revenues is pegged at $2.77 billion, signaling a 7.3% increase.
Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank of 2.
The Zacks Consensus Estimate for Cardinal Health’s bottom line for the to-be-reported quarter suggests 16.4% year-over-year growth. Its earnings beat estimates in each of the past four quarters, with an average surprise of 10.3%. CAH’s revenues for the to-be-reported quarter are pegged at $65.61 billion, a 9.1% increase from the year-ago period.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company's payer mix, which impacted revenue by approximately $400 million in the quarter.
On this news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
